TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula(I) which are tropomyosin-related kinase(Trk)family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF)receptor TrkA..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Europäisches Patentamt - (2022) vom: 27. Apr. Zur Gesamtaufnahme - year:2022 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
LI CHUN SING [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-04-27, Last update posted on www.tib.eu: 2022-08-23, Last updated: 2023-02-09 |
---|
Patentnummer: |
EP3122344 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA006157149 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA006157149 | ||
003 | DE-627 | ||
005 | 20230503170556.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210531s2022 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA006157149 | ||
035 | |a (EPA)EP3122344 | ||
035 | |a (EPA)54193893 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a LI CHUN SING |e verfasserin |4 aut | |
245 | 1 | 0 | |a TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2022-04-27, Last update posted on www.tib.eu: 2022-08-23, Last updated: 2023-02-09 | ||
520 | |a The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula(I) which are tropomyosin-related kinase(Trk)family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF)receptor TrkA. | ||
650 | 4 | |a che | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a 615 | |
700 | 0 | |a MITCHELL HELEN |4 aut | |
700 | 0 | |a WOOD HAROLD B |4 aut | |
700 | 0 | |a MAO QINGHUA |4 aut | |
700 | 0 | |a QI ZHIQI |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 27. Apr. |
773 | 1 | 8 | |g year:2022 |g day:27 |g month:04 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/54193893/publication/EP3122344A1?q=EP3122344 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
912 | |a SSG-OLC-PHA | ||
936 | u | w | |j 2022 |b 27 |c 04 |
951 | |a AR | ||
952 | |j 2022 |b 27 |c 04 |